Top Companies in the Short Bowel Syndrome Market Is Essential for Your Success. Read this to find out why
Short Bowel Syndrome Market by Drug Class (GLP-2, Growth Hormone, Glutamine, Others), By Region (North America, Europe, Asia Pacific, Latin America)
Coralia.Joe
Market Overview:
According to Vantage market research, the Global Short Bowel Syndrome market is valued at USD 1.02 Billion in 2021 and is projected to attain a value of USD 2.97 Billion by 2028 at a CAGR of 18.1% during the forecast period, 2022–2028. Short bowel syndrome can happen when portions of the small intestine have been surgically removed and this can be happened by surgical removal of large portions of the small intestine in diseases such as cancer, traumatic injuries, blood clots in the arteries, and Crohn's disease. According to the National Institute of Diabetes and digestive and kidney diseases, short bowel syndrome affects about three out of every million people each year. Thus, the emergence of short bowel syndrome has been increased rapidly across the globe and further propelling the growth of Short Bowel Syndrome Market in recent years.
North America is predicted to witness the largest share of the Short Bowel Syndrome Market during the forecast period. The availability of a strong healthcare system and reimbursement policies in this region is augmenting the high growth of the Short Bowel Syndrome Market in recent years. In addition, the availability of a large number of market players is accounting for maximum market growth in this region. For instance, Takeda Pharmaceutical Company Limited, acquired Shire plc, becoming a global, to expand its geographic footprint and leading position in Japan and the U.S. for bringing its highly-innovative medicines to around 80 countries/regions with dedicated employees across the world.
Following are the top 8 companies in the Short Bowel Syndrome market:
|
Company Name |
Revenue in USD |
|
$18 Billion |
|
<$5 Million |
|
<$5 Million |
|
$353 Million |
|
$20 Billion |
|
$69 Billion |
|
$10 Million |
|
$46 Million |
|
<$5 Million |
The Takeda Pharmaceutical Company Limited is an American- Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology.
OxThera AB was founded in 2005 to explore the therapeutic potential that originated from this observation. Turning a naturally occurring bacteria into a healthcare product may sound easy, but in reality, it is not. To commercialize Oxabact®, they needed to develop a large-scale manufacturing process and a suitable delivery mechanism to transport uniform quantities of live bacteria to the site of action. The bacterium viability demands strict anaerobe conditions making bio-manufacturing complex. The company has developed a lyophilized formulation encapsulated in a special enteric coating that protects the bacteria from stomach acid. The capsule remains intact while passing through the stomach, then releases cells at the target site.
VectivBio AG is a global, clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative treatments for severe rare conditions with high unmet medical needs. The company is committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies tailored to patients’ needs. The company is headquartered in Basel, Switzerland, with business operations in the New York area.
Nutrinia is a neonatology-focused company that treats rare conditions of the gastrointestinal tract. The company is developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. The products of the company in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. The company believes that science is best used to make life better for people, especially the most vulnerable populations.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 57,000 employees and present in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences, and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German immigrants, Charles Pfizer and his cousin Charles F. Erhart. The company develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues.
Ardelyx is dedicated to improving the lives of patients by discovering, developing, and commercializing first-in-class targeted therapies that advance patient care. Using the company's discovery model, Ardelyx scientists identified new biological mechanisms and pathways that enabled to development of drug candidates designed to address significant unmet medical needs with the goal of improving outcomes for patients. The company fosters a culture of compliance and holds our employees, contractors, and other representatives acting on the company's behalf to a high standard of business and professional conduct.
Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company intends to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other rare disease areas with significant unmet medical needs. The company employs more than 300 people in Denmark and the US and has a portfolio of medicines and product candidates, including license collaborations with Boehringer Ingelheim. The company is focusing on gastrointestinal, metabolic, and other specialty diseases where they believe that the present standard of care is inadequate and where they have the resources to advance their peptide-based product candidates into the later stages of clinical development, including registration and commercialization, while opportunistically considering partnership relationships that may arise. In addition, the company is looking to focus its efforts on drug candidates that may qualify for orphan/rare disease status. The company's research and development, the organization is structured to enable dynamic collaboration across various functions and project teams at each stage of discovery and development, allowing us to advance promising opportunities quickly and take advantage of their extensive knowledge of peptide design and product development.
Nestlé S.A. is a Swiss multinational food and drinks processing conglomerate corporation headquartered in Vevey, Vaud, Switzerland. It is the largest food company in the world, measured by revenue and other metrics. The company's products include baby food (some including human milk oligosaccharides), medical food, bottled water, breakfast cereals, coffee and tea, confectionery, dairy products, ice cream, frozen food, pet foods, and snacks. The company has 447 factories, operates in 189 countries, and employs around 339,000 people. It is one of the main shareholders of L'Oreal, the world's largest cosmetics company.
Get Free Sample Here: https://www.vantagemarketresearch.com/short-bowel-syndrome-market-1318/request-sample
For More Information about each of these companies. Vantage Market Research Report comes up with a detailed analysis of each major player in the industry. The Study provides Global market size & share, Emerging trends, In-depth analysis of key players, Development opportunities, Sales, Revenue Forecast.
